Lead Product(s): Ripretinib
Therapeutic Area: Oncology Product Name: Qinlock
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 06, 2020
Deciphera Pharmaceuticals will distribution and commercialize QINLOCK, a switch-control tyrosine kinase inhibitor, in Canada and Israel for the treatment of fourth-line gastrointestinal stromal tumor (GIST).